SYNTHESIS OF NOVEL 4,6-DIPHENYLPYRIMIDINE SUBSTITUTED BENZAMIDE DERIVATIVES ITS CHARACTERIZATION AND EVALUATION FOR ANTI-OXIDANT AND ANTI-MICROBIAL ACTIVITIES

Abstract

The research work involves the estimation and evaluation of pharmacological activity of designed 4, 6-diphenylpyrimidine substituted benzamide derivatives that act as HDAC inhibitors. The Histone deacetylases inhibitors are a new class of cytostatic agents that exhibits promising results cancer treatment. The four HDAC inhibitors approved by FDA for cancer chemotherapy is SAHA (Vorinostat), Belinostat (PXD-101), Panobinostat (LBH-589), and Romidepsin (FK-228). The six novel 4, 6-diphenylpyrimidine substituted benzamide derivatives were synthesized, characterized and evaluated for anti-microbial and anti-oxidant activities. The designed molecule with cap group as substituted 4, 6-diphenylpyrimidine of functional groups adjacent to the metal-binding benzamide was evaluated for the pharmacological activity evaluation. Prior to this, the work was done on in-silico studies by molecular docking and confirmed the anti-cancer activity. The Anti-oxidant and Anti-microbial activity was evaluated as per standard methods. Anti-microbial activities involve the Anti-bacterial and Anti-fungal activity estimation. Hence, based on the pharmacological activity results, it is confirmed that the designed and characterized novel 4, 6-diphenylpyrimidine substituted benzamide exhibited the biological activity of Anti-oxidant and Anti-microbial activity.